Fabrication and study of release kinetics of moxifloxacin and dexamethasone loaded nanostructured lipid carrier system for ocular drug delivery
Abstract
Background: The combination of moxifloxacin hydrochloride (MOX) and dexamethasone sodium phosphate (DEX) is widely available in the conventional commercial market for treating ocular infections and inflammations. Traditional ocular delivery systems are inferior to nanostructured lipid carriers (NLCs) due to their poor drug bioavailability, rapid tear drainage, and limited drug penetration. In contrast, NLCs offer sustained release, enhanced corneal absorption, and improved drug stability. Thus, the research aims to develop moxifloxacin and dexamethasone-loaded NLC for effective drug release. Methodology: In this study, a combination of MOX and DEX drugs was loaded in an NLC. The NLC was prepared using standard methods and evaluated for characteristic properties, including particle size (PS), polydispersity index (PDI), entrapment efficiency (EE), and drug loading (DL), as well as drug encapsulation and in vitro studies. Results and Discussion: The optimized formulation of NLC possessed a particle size of 190.58 nm and a polydispersity index of 26.7%. The fabricated drug exhibited a KP model release kinetics, indicating that drug release occurred via a combination of diffusion and polymer reaction. The NLC also exhibited a PDI of 26.7%, indicating a moderately uniform particle size distribution, which further suggests a consistent particle size, an acceptable characteristic for nano-carrier systems. The FT-IR analysis revealed optimal encapsulation of drugs inside the lipids,…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.